Boehringer Ingelheim Reports Strong 2024 Growth, Reaffirms Long-Term Animal Health Investment Strategy

05/04/2025

Boehringer Ingelheim has reported a strong 6.1% growth in 2024, with net sales reaching €26.8 billion, demonstrating its ongoing success in both human and animal health. The company continues to focus on innovative health solutions for both people and animals, impacting millions globally through its portfolio of vaccines, therapeutics, and parasiticides. With substantial R&D investments driving its pipeline, Boehringer reaffirms its commitment to tackling global health challenges while shaping the future of animal health in the global food economy.

According to Frank Huebler, Member of the Board of Managing Directors, the company achieved net sales of €26.8 billion, marking a 6.1% growth year-over-year. While these figures reflect solid commercial execution, they also point to growing global demand for innovative health solutions across both human and veterinary medicine.

Scaling Impact Across Species

One of the standout highlights from Huebler’s announcement was the company’s impact on 66 million human patients—and “many more millions of animals” in 2024 alone. This underscores Boehringer’s dual focus and unique ability to scale outcomes across species, linking its portfolio of parasiticides, vaccines, and therapeutics to better health and improved productivity in livestock, companion animals, and beyond.

A Pipeline Fueled by Investment

The company’s “historically rich pipeline” is being further strengthened with substantial R&D investments, aimed at accelerating innovation in biologics, precision medicine, and preventative health. For animal health stakeholders, this signals a continuing commitment to tackling persistent challenges like antimicrobial resistance, zoonotic diseases, and emerging livestock threats—all of which have economic implications for the global protein supply chain.

Business Outlook: Stability Meets Strategy

In a volatile global market, Boehringer’s performance provides a case study in balancing resilient operations with forward-looking investment. For agri-food producers, veterinarians, and feed industry professionals, this translates into access to more consistent, research-backed solutions that support both animal welfare and business viability.

With innovation, scale, and strong economic fundamentals, Boehringer Ingelheim continues to shape the future of animal health—not just as a science-driven company, but as a strategic partner in the global food economy.